Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: United Kingdom, Brazil, Europe, France, Canada
The demand for Anti-Fibrinolytic Drugs in Kuwait has been on the rise in recent years.
Customer preferences: The increase in demand for Anti-Fibrinolytic Drugs can be attributed to the growing aging population in Kuwait. With the increase in age, the likelihood of developing medical conditions such as bleeding disorders and cardiovascular diseases also increases. As a result, there has been a surge in demand for Anti-Fibrinolytic Drugs that help in preventing excessive bleeding.
Trends in the market: The Anti-Fibrinolytic Drugs market in Kuwait has been experiencing a shift towards the use of generic drugs. This trend is similar to what is being observed in other regions globally. The shift towards generic drugs is driven by the need to reduce healthcare costs. Additionally, there has been an increase in the number of local pharmaceutical companies that are manufacturing generic Anti-Fibrinolytic Drugs. This has resulted in increased competition and lower prices for consumers.
Local special circumstances: Kuwait has a well-developed healthcare system that is heavily subsidized by the government. As a result, the cost of healthcare in Kuwait is relatively low compared to other countries in the region. This has made it easier for consumers to access Anti-Fibrinolytic Drugs.
Underlying macroeconomic factors: The Kuwaiti economy is heavily dependent on oil exports. The recent decline in oil prices has resulted in a slowdown in the economy. However, the government has been investing heavily in infrastructure projects to diversify the economy. This has resulted in an increase in job opportunities and an increase in disposable income. This, in turn, has led to an increase in healthcare expenditure, including the purchase of Anti-Fibrinolytic Drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)